Trarbach, T., Major, P., Lenz, H., Kerr, D., Pendergrass, K., Douillard, J., Chen, B., Littlewood-Evans, A., Laurent, D., Jacques, C., & Van Cutsem, E. (2016). A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS. 17, 122–122.

Trarbach, T., et al. A Meta-Analysis of Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Receiving FOLFOX4 and PTK/ZK to Determine Clinical Benefit on Progression-Free Survival (PFS) in High LDH PTS. 2016, pp. 122–22.

Trarbach, T, P Major, H Lenz, D Kerr, K Pendergrass, J Douillard, B Chen, et al. 2016. “A Meta-Analysis of Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Receiving FOLFOX4 and PTK/ZK to Determine Clinical Benefit on Progression-Free Survival (PFS) in High LDH PTS.” In , 17:122–22.